# Efficacy and Safety of PG-530742 in the Treatment of Mild to Moderate Knee Osteoarthritis

> **NCT00041756** · PHASE2 · COMPLETED · sponsor: **Procter and Gamble** · enrollment: 395 (actual)

## Conditions studied

- Osteoarthritis, Knee

## Interventions

- **DRUG:** PG-530742
- **DRUG:** Placebo
- **DRUG:** 50 mg PG-530742
- **DRUG:** 100 mg PG-530742
- **DRUG:** 200 mg PG-530742

## Key facts

- **NCT ID:** NCT00041756
- **Lead sponsor:** Procter and Gamble
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-07
- **Primary completion:** 2004-02
- **Final completion:** 2004-02
- **Target enrollment:** 395 (ACTUAL)
- **Last updated:** 2011-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00041756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00041756, "Efficacy and Safety of PG-530742 in the Treatment of Mild to Moderate Knee Osteoarthritis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00041756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*